Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, Penumbra (PEN) reported revenue of $324.14 million, up 16.3% over the same period last year. EPS came in at $0.83, compared to $0.41 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $315.71 million, representing a surprise of +2.67%. The company delivered an EPS surprise of +25.76%, with the consensus EPS estimate being $0.66.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Penumbra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- International: $67.28 million compared to the $68.99 million average estimate based on three analysts. The reported number represents a change of -2.5% year over year. Geographic Revenue- United States: $256.86 million versus $247.36 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +22.5% change. Revenue- Thrombectomy - United States: $187.89 million versus the three-analyst average estimate of $181.26 million. Revenue- Embolization and Access - United States: $68.97 million compared to the $66.09 million average estimate based on three analysts. Revenue- Thrombectomy - International: $38.65 million versus $37.61 million estimated by two analysts on average. Revenue- Embolization and Access - International: $28.63 million compared to the $31.28 million average estimate based on two analysts. Revenue- Embolization and Access: $97.60 million versus $96.87 million estimated by two analysts on average. Revenue- Thrombectomy: $226.54 million versus the two-analyst average estimate of $219.45 million. View all Key Company Metrics for Penumbra here>>>Shares of Penumbra have returned -2.2% over the past month versus the Zacks S&P 500 composite's -6.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks